Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)

An urgent need exists for antibiotics to treat infections caused by carbapenem-resistant Acinetobacter baumannii–calcoaceticus complex (ABC). Sulbactam–durlobactam is a β-lactam–β-lactamase inhibitor combination with activity against Acinetobacter, including multidrug-resistant strains. In a phase 3...

Ausführliche Beschreibung